

S W I S S C A N C E R C E N T E R

LEMAN

# **PROGRAM** 13TH FACULTY & STAFF ANNUAL RETREAT SWISS CANCER CENTER LEMAN

sponsored by ISREC Foundation

September 26 & 27, 2024 SwissTech Convention Center



## **THURSDAY 26 SEPTEMBER**

## 08:20 - 08:50 WELCOME COFFEE

8:50	WELCOME REMARKS: David Gfeller
9:00-10:15	SOMMET DU MOLÉSON Chair: Benita Wolf
9:00	Immune regulation of CCR7+ dendritic cells at tumor sites. <b>Zitti Béatrice</b> , <i>Mikael Pittet group</i> , <i>UNIGE</i> .
9:15	CytoxPred: an AI-based computational method to predict cancer cell lines sensitivity to cytotoxic compounds. <b>Cuozzo Alessandro</b> , <i>Vincent Zoete group, UNIL</i>
9:30	Unraveling the molecular basis of cross-reactivity in TCR epitope recognition. <b>Liu Yan</b> , <i>David Gfeller group</i> , UNIL
9:45	Wounding triggers invasive progression in human basal cell carcinoma. Yerly Laura, <i>François Kuonen group, CHUV</i>
10:00	Pharmacological modulation by BTK inhibitor induces the upregulation of CD19 and increases sensitivity to CAR T cells in B cell lymphomas. Wang Sisi, <i>Federico Simonetta group, UNIGE</i>

## 10:15 – 11:00 COFFEE BREAK

11:00-12:15	SOMMET DU MONT-TENDRE Chair: Josep Garnica
11:00	FMRP Upregulation in Cancer: Implicating FMRP-expressing Cancer-Associated Fibroblasts in Immune Evasion. Yucel Simge, Douglas Hanahan group, EPFL
11:15	Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Larrue Clément, Tamburini Jerome group, UNIGE
11:30	Engineering human hematopoietic stem and progenitor cells as a cellular therapy to reprogram the myeloid compartment of solid cancers. Faria Carla, <i>Bernhard Gentner group, CHUV</i>
11:45	Transcription–replication conflicts underlie sensitivity to PARP inhibitors. <b>Petropoulos Michalis</b> , <i>Thanos Halazonetis group</i> , <i>UNIGE</i>
12:00	Rationally designed CD70 CARs against acute myeloid leukemia. <b>Que Tiffany</b> , <i>Caroline Arber group, UNIL/CHUV</i>

## 12:15 - 13:30 LUNCH

12:15-15:00	POSTER SESSION
15:00-16:15	SOMMET DU ROCHER DE NAYE Chair: Weilin Li
15:00	Circadian immune cell dynamics in the tumor microenvironment <b>Zeng Qun</b> , <i>Christoph Scheiermann group, UNIGE</i>

15:15	Nonsense-mediated mRNA decay inhibition via Smg6 triggers adaptive and innate immune responses through distinct mechanisms and prevents hepatocellular cancer development <b>Arpa Enes Salih</b> , <i>David Gatfield group, UNIL</i>
15:30	Impaired function of CD8+ T cells under acidic conditions is associated with a lowering in IL-2 responsiveness, c-Myc levels and mTORC1 signaling. Vuillefroy de Silly Romain, Melita Irving group, Ludwig Institute for Cancer Research.
15:45	Modulation of Activin-A processing by allosteric disulfide bonds and their role in regulating melanoma growth. Bulliard Manon, Daniel Constam group, EPFL
16:00	Mitochondrial rearrangement driven by cardiolipin depletion enhances drug resistance in lung adenocarcinoma. Falco Simone, <i>Georgia Konstantinidou group, UNIBE</i>

## 16:15 - 17:00 COFFEE BREAK

17:00-17:45	KEYNOTE SPEAKER Chair: Michelle de Palma
17:00	Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance. <b>Stefani Spranger</b> , Koch Institute for Integrative cancer Research and Ludwig Center at Massachusetts Institute of Technology

## 17:45 – 20:00 COCKTAIL DINATOIRE

## **FRIDAY 27 SEPTEMBER**

## 08:45 - 09:00 WELCOME COFFEE

9:00-10:30	SOMMET DU SALÈVE Chair: Daniel Tadros
9:00	Insights into the mechanism of action of a withanolide derivative in multiple myeloma. <b>Zingg Albane</b> , <i>Muriel Cuendet group, UNIGE</i>
9:15	Redefining Cell Types and States through Single-Cell Omics. Garnica Josep, Santiago Carmona group, UNIL/CHUV
9:30	Aiding and aBETting metastasis: Epigenetic-driven awakening in ER+ breast cancer. <b>Quinn Hazel</b> , <i>Cathrin Brisken group, EPFL</i>
9:45	Development of Methotrexate Nanoparticles for the treatment of Gestational Trophoblastic Neoplasia. Boukaoui Doha, Marie Cohen group, UNIGE.
10:00	Unlocking NK cell potential in hematological cancers through modulation of PSMB9 Kasapoglu Asli, <i>Elisa Oricchio group, ISREC EPFL</i>
10:15	Minor intron splicing is critical for survival of lethal prostate cancer. <b>Augspach Anke</b> , <i>Mark Rubin group</i> , UNIBE

## 10:30 - 11:00 COFFEE BREAK

11:00-13:15 POSTER SESSION

#### 12:00 - 13:15 LUNCH

13:15-15:15	SOMMET DU MONT-BLANC Chair: Evangelia Bolli
13:15	Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics <b>Shapiro Ilja</b> , <i>Michal Bassani-Sternberg group, UNIL/CHUV</i>
13:30	Impact of surgery on the use of immune checkpoint inhibitors against hepatocellular carcinoma. <b>El Hajji Sofia</b> , <i>Christian Toso group, UNIGE</i>
13:45	Proteomic profiling of diffuse midline glioma for improved therapeutic decision making <b>Izac Findlay</b> , <i>Sebastian Waszak group, EPFL</i>
14:00	Stromal reprogramming and arterial Notch signaling inhibition drive TLS neogenesis during anti- angiogenic immunotherapy Mahfoud Samantha, <i>Tatiana Petrova group, UNIL</i>

### 14:15 – 14:30 SHORT BREAK

14:30	Targeting the Wnt pathway with selective FZD inhibitors in TNBC and colorectal cancer. <b>Poinot Hélène</b> , <i>Vladimir Katanaev group, UNIGE</i>
14:45	Investigating the niche of drug-tolerant tumor-repopulating cells to eradicate residual disease in BRCA1;p53-deficient mammary tumors <b>Decollogny Morgane,</b> <i>Sven Rottenberg group, UNIBE</i>
15:00	Engineering of mechanically reinforced adoptive T-cell therapies Bonati Lucia, Li Tang group, EPFL

### 15:15 - 15:30 SHORT BREAK

15:30	BEST TALK & POSTERS AWARDS: Douglas Hanahan
15:45	CLOSING REMARKS: David Gfeller

AdipoGen®

